期刊
BMJ OPEN
卷 4, 期 3, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2013-003758
关键词
Epidemiology; Health Economics; Public Health
资金
- Italian Minister for University and Research (Fondo d'Ateneo per la Ricerca portion)
Objective Adherence with bisphosphonates therapy is generally low. Enhancing adherence with bisphosphonates would be effective in achieving the full benefits of therapy albeit a growth in the expenditure for supporting incremented drug use is expected. The cost-effectiveness of enhancing adherence with oral bisphosphonates in a large population of osteoporotic women has been assessed in the current study. Design Retrospective cohort study. Setting Healthcare utilisation databases of Lombardy Region, Italy. Participants A cohort of 28 558 women aged 45 years or more, resident in the Italian Region of Lombardy, who were newly treated with oral bisphosphonates during 2003-2004, was followed for 6 years after index prescription. Outcome measures Fracture-free survival time, healthcare cost and incremental cost-effectiveness ratio (ICER) of enhancing adherence, that is, the additional cost that would be spent every year for gaining one fracture-free year as a consequence of enhancing adherence at a certain level. Results Enhanced adherence from 33% (baseline) to 80%, increased both fracture-free survivals from 970 to 973 years and healthcare costs from euro118 000 to euro265 000 every 1000 woman-years, with ICER value of euro53 000 (95% CI euro49 000 to euro58 000). ICER values were lower for older women (euro50 000; 95% CI euro42 000 to euro58 000) and for those suffering from at least a chronic comorbidity (euro25000; 95% CI 95% CI euro7000 to euro47 000). Conclusions Enhancing adherence with oral bisphosphonates offers important benefits in reducing the risk of fracture, although at a substantial cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据